Yamini Kalla, MD
Infectious Disease · Abilene, TXNPI 1568420693
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 21 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 10 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $287 and has fallen 59.9% since, to $115 in 2025. That places this record below the midpoint for infectious disease clinicians in TX, where the typical reported total is $451.
Across 21 payments — averaging $25.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$106
- AbbVie$94
- Astellas Pharma US Inc$72
- Amgen$57
- Tetraphase Pharmaceuticals, Inc.$54
- Pfizer$48
- plus $100 from 4 others
What the payments were for
- Food & beverage$51898%
- Education$132%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 6 | $106 |
| AbbVie | 1 | $94 |
| Astellas Pharma US Inc | 4 | $72 |
| Amgen | 2 | $57 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $54 |
| Pfizer | 2 | $48 |
| Eisai Inc. | 1 | $33 |
| Viiv Healthcare Company | 2 | $27 |
| Tandem Diabetes Care, Inc. | 1 | $23 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
How this compares
$531 in reported general payments places this provider in the 50th percentile of 576 infectious disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 39 | $144,604 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 13 | $50,721 |
| Cefazolin Sodium | 11 | $610 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 23 | $141 |
| Furosemide | 62 | $119 |
| Cephalexin | 12 | $53 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Abilene
- Elizabeth RaceDallas$1.5M
- Ogechika AlozieEl Paso$834K
- Joseph GatheHouston$695K
- Roy ChemalyHouston$686K
- Cedric SpakFort Worth$427K
- Ben BarnettHouston$424K
- Uriel SandkovskyDallas$320K
- Amar SafdarHouston$284K
- Roger BedimoDallas$269K
- Miguel Sierra-HoffmanVictoria$238K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.